Publications

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, Hiv-1-Infected Adults: 48-Week Results From the Assert Study

AuthID
P-003-3H6

Author(s)

Post, FA

Moyle, GJ

Stellbrink, HJ

Domingo, P

Fisher, M

Rieger, A

Branco, T

Pearce, HC

Givens, N

Vavro, C

Lim, ML

Document Type

Article

Year published

2010

Published

in JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, ISSN: 1525-4135

Volume: 55, Issue: 1, Pages: 49-57 (9)

Conference

12Th European Aids Conference/European-Aids-Clinical-Society (Eacs), Date: NOV 11-24, 2009, Location: Cologne, GERMANY, Sponsors: European AIDS Clin Soc

Indexing

Wos^®

Scopus^®

Crossref^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1097/qai.0b013e3181dd911e

Pubmed: 20431394

Scopus: 2-s2.0-77956637582

Wos: WOS:000281170500006

Source Identifiers

ISSN: 1525-4135

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, Hiv-1-Infected Adults: 48-Week Results From the Assert Study

Useful Links

Get Help

Federated Authentication (Click on the image)

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, Hiv-1-Infected Adults: 48-Week Results From the Assert Study

Useful Links

Get Help